The Centers for Disease Control and Prevention's new guidelines for sexually transmitted diseases stress the importance of early screening, diagnosis and treatment.
The Centers for Disease Control and Prevention's new guidelines for sexually transmitted diseases stress the importance of early screening, diagnosis and treatment.
The "1998 Guidelines for Treatment of Sexually Transmitted Diseases," updated for the first time since 1993, address several points raised in the Institute of Medicine's 1997 report on the epidemic of STDs in the United States, including consistency and adequacy of care.
Notable changes in treatment outlined in the guidelines include endorsement of single-dose oral therapies for nearly all common, curable STDs.
The guidelines also draw attention to improved treatments for herpes and human papilloma virus. New, recommended therapies may be applied by patients themselves, and may reduce the emotional stress associated with sexually transmitted diseases.
The Centers for Disease Control and Prevention recommends implementing simple urine tests in clinical and non-clinical settings to test for chlamydia. These newer tests may be especially effective in testing in high schools, for example, where large groups of adolescents might be tested. Adolescents, the guidelines note, are at greatest risk for the infection. In one study, as many as one in eight teenage girls tested positive for chlamydia.
The guidelines also recommend more aggressive vaccination of sexually active young people, who are at high risk for hepatitis A and hepatitis B.
Finally, the newer guidelines detail the advances possible in the treatment of STDs during pregnancy. Newer treatments for chlamydia cause fewer side effects, and better screening and treatment of bacterial vaginosis among women with histories of preterm births reduces the number of infants born prematurely as a result of the disease.
Identifying and treating STDs in the estimated 12 million Americans who are infected with them each year can greatly reduce the risks of infertility, potentially fatal tubal pregnancies and debilitating diseases in infants, according the Centers for Disease Control and Prevention.
It may even reduce the contraction and spreading of HIV among women.
The Centers for Disease Control and Prevention will disseminate the new guidelines more aggressively than in years past, officials said.
For more information, physicians and other health care professionals may view the complete guidelines on the Internet at www.cdc.gov./nchstp/dstd/dstdp.html, or order by fax, (404) 639-8628. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.